Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Inventory (2016 - 2026)

Cytosorbents filings provide 15 years of Inventory readings, the most recent being $5.3 million for Q4 2025.

  • On a quarterly basis, Inventory rose 93.23% to $5.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.3 million, a 93.23% increase, with the full-year FY2025 number at $5.3 million, up 93.23% from a year prior.
  • Inventory hit $5.3 million in Q4 2025 for Cytosorbents, up from $4.0 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $5.4 million in Q1 2022 to a low of $1.7 million in Q1 2023.
  • Median Inventory over the past 5 years was $3.6 million (2021), compared with a mean of $3.7 million.
  • Biggest five-year swings in Inventory: skyrocketed 123.59% in 2021 and later tumbled 68.31% in 2023.
  • Cytosorbents' Inventory stood at $4.8 million in 2021, then decreased by 27.37% to $3.5 million in 2022, then decreased by 2.48% to $3.4 million in 2023, then fell by 19.04% to $2.7 million in 2024, then soared by 93.23% to $5.3 million in 2025.
  • The last three reported values for Inventory were $5.3 million (Q4 2025), $4.0 million (Q3 2025), and $3.7 million (Q2 2025) per Business Quant data.